Print this page
-
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer.
Protocol: 072505Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (pf-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072510Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Pancreas -
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer.
Protocol: 072509Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Other Digestive Organ -
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (pf-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072510Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Pancreas -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis STOPGAP II
Protocol: 072603Principal Investigator:
- Haejin In
Applicable Disease Sites: Esophagus
Stomach -
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis STOPGAP II
Protocol: 072603Principal Investigator:
- Haejin In
Applicable Disease Sites: Esophagus
Stomach -
Expanded Access Program To Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Draxonrasib.
Protocol: 072605Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Pancreas -
Expanded Access Program To Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Draxonrasib.
Protocol: 072605Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Pancreas -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
PIONEER (Preparing for Implementation and Optimization of aNal scrEEning and tReatment)
Protocol: 132311Principal Investigator:
- Racquel Kohler
Applicable Disease Sites: Anus -
Tracking Health and Resilience in Metastatic Colorectal Cancer: THRIVE-MCRC
Protocol: 132314Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon -
Biopsychosocial Study to Track Health and Responses to Living with Cancer in New Jersey (BioTHRIVE-NJ)
Protocol: 132416Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon
Rectum